Neose to sell two compounds to Novo Nordisk, BioGenerix

PHILADELPHIA Neose Technologies will sell the rights to compounds it had developed with two European companies as its stock trades for just over 20 cents.

The biotech, based in Horsham, Pa., will sell the compounds to Danish drug maker Novo Nordisk and German biotech BioGenerix, with which it had deals to develop the compounds for treating the immune disorder neutropenia and for inhibiting bleeding.

The company was founded in 1990 and went public in 2000.